Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2019

01-10-2019 | Gastric Cancer | Original Article

β-Secretase 1 and its Naturally Occurring Anti-Sense RNA are Down-Regulated in Gastric Cancer

Authors: Farbod Esfandi, Soudeh Ghafouri-Fard, Vahid Kholghi Oskooei, Mohammad Taheri

Published in: Pathology & Oncology Research | Issue 4/2019

Login to get access

Abstract

β-secretase (BACE1) and its naturally occurring anti-sense RNA (BACE1-AS) have established role in the pathologic process leading to Alzheimer’s disease. Their possible implication in the neoangiogenesis suggests that they might be involved in the tumorigenesis events as well. In the present study, we compared transcript levels of these genes in 30 gastric cancer samples and their adjacent non-cancerous tissues (ANCTs) to find whether their altered expression might facilitate discrimination of these two sets of samples. Expressions of both genes were associated with site of primary tumor. Both genes were significantly down-regulated in tumoral tissues compared with ANCTs. Significant correlations were detected between transcript levels of these genes in both sets of samples. Transcript levels of BACE1 and BACE1-AS had the diagnostic power of 75% based on Receiver operating characteristic curve analysis. The current study provides evidences for contribution of BACE1 and BACE1-AS in gastric cancer evolution and suggests their potential as diagnostic markers.
Literature
1.
Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314:664–666CrossRef
2.
John V (2006) Human beta-secretase (BACE) and BACE inhibitors: progress report. Curr Top Med Chem 6:569–578CrossRef
3.
Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, Laurent GS III, Kenny PJ, Wahlestedt C (2008) Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of β-secretase. Nat Med 14:723–730CrossRef
4.
Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M (2005) Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur J Pharmacol 514:1–15CrossRef
5.
Nienhuser H, Schmidt T (2018) Angiogenesis and anti-angiogenic therapy in gastric cancer. Int J Mol Sci 19(1):43
6.
Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W (2006) Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103:18727–18732CrossRef
7.
Zhang X, Zhou K, Wang RS, Cui JK, Lipton SA, Liao FF, Xu HX, Zhang YW (2007) Hypoxia-inducible factor 1 alpha (HIF-1 alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 282:10873–10880CrossRef
8.
Kitajima Y, Miyazaki K (2013) The critical impact of HIF-1a on gastric cancer biology. Cancers (Basel) 5:15–26CrossRef
9.
Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, Takiguchi S, Yasuda T, Yano M, Monden M (2006) Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 9:44–49CrossRef
10.
Rossner S, Sastre M, Bourne K, Lichtenthaler SF (2006) Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer’s disease. Prog Neurobiol 79:95–111CrossRef
11.
Lange-Dohna C, Zeitschel U, Gaunitz F, Perez-Polo JR, Bigl V, Rossner S (2003) Cloning and expression of the rat BACE1 promoter. J Neurosci Res 73:73–80CrossRef
12.
Huang T, Kang W, Zhang B, Wu F, Dong Y, Tong JH, Yang W, Zhou Y, Zhang L, Cheng AS, Yu J, K.F. To (2016) miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-kappaB signaling in gastric carcinogenesis. Mol Cancer 15:9CrossRef
13.
Sharma SA, Tummuru MK, Blaser MJ, Kerr LD (1998) Activation of IL-8 gene expression by helicobacter pylori is regulated by transcription factor nuclear factor-kappa B in gastric epithelial cells. J Immunol 160:2401–2407PubMed
14.
Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, Sakai H, Ren CY, Yuasa Y, Herman JG, Baylin SB (2003) GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 23:8429–8439CrossRef
15.
Mei Z, Yan P, Tan X, Zheng S, Situ B (2015) Transcriptional regulation of BACE1 by NFAT3 leads to enhanced amyloidogenic processing. Neurochem Res 40:829–836CrossRef
16.
Robbs BK, Cruz AL, Werneck MB, Mognol GP, Viola JP (2008) Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol 28:7168–7181CrossRef
17.
Zali H, Rezaei-Tavirani M, Vafaee R, Rezaei-Tavirani M (2013) Gastric cardia adenocarcinoma pathway analysis. Gastroenterol Hepatol Bed Bench 6:S11–S18PubMedPubMedCentral
Metadata
Title
β-Secretase 1 and its Naturally Occurring Anti-Sense RNA are Down-Regulated in Gastric Cancer
Authors
Farbod Esfandi
Soudeh Ghafouri-Fard
Vahid Kholghi Oskooei
Mohammad Taheri
Publication date
01-10-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00621-4

Other articles of this Issue 4/2019

Pathology & Oncology Research 4/2019 Go to the issue

Letter to the Editor

Absence of Promoter Mutation in TBC1D12 Gene in Solid and Hematologic Neoplasia

Letter to the Editor

Oral Potentially Malignant Disorder Based Customized Epithelial Dysplasia Grading: a Need of the Hour

Original Article

Promoter DNA Methylation and mRNA Expression Level of p16 Gene in Oral Squamous Cell Carcinoma: Correlation with Clinicopathological Characteristics

Original Article

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer

Original Article

Polymorphism of DNA Repair Genes via Homologous Recombination (HR) in Ovarian Cancer

Original Article

Comparative Study of Different Classification Models in Renal-Cell Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits